Join today and have your say! It’s FREE!

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Please Try Again
{{ error }}
By providing my email, I consent to receiving investment related electronic messages from Stockhouse.

or

Sign In

Please Try Again
{{ error }}
Password Hint : {{passwordHint}}
Forgot Password?

or

Please Try Again {{ error }}

Send my password

SUCCESS
An email was sent with password retrieval instructions. Please go to the link in the email message to retrieve your password.

Become a member today, It's free!

We will not release or resell your information to third parties without your permission.
Quote  |  Bullboard  |  News  |  Opinion  |  Profile  |  Peers  |  Filings  |  Financials  |  Options  |  Price History  |  Ratios  |  Ownership  |  Insiders  |  Valuation

Theratechnologies Inc T.TH

Alternate Symbol(s):  THTX

Theratechnologies Inc. is a Canada-based clinical-stage biopharmaceutical company. The Company is focused on the development and commercialization of therapies addressing unmet medical needs. It markets prescription products for people with human immunodeficiency viruses (HIV) in the United States. The Company's research pipeline focuses on specialized therapies addressing unmet medical needs in HIV, nonalcoholic steatohepatitis (NASH) and oncology. Its medicines include Trogarzo and EGRIFTA SV (tesamorelin for injection). Trogarzo (ibalizumab-uiyk) injection is a long-acting monoclonal antibody which binds to domain 2 of the CD4 T cell receptors. EGRIFTA SV (tesamorelin for injection) is approved in the United States for the reduction of excess abdominal fat in people with HIV who have lipodystrophy. Its portfolio includes Phase I clinical trial of sudocetaxel zendusortide (TH1902), a novel peptide-drug conjugate (PDC), in patients with advanced ovarian cancer.


TSX:TH - Post by User

Post by scarlet1967on Jan 13, 2022 9:04am
133 Views
Post# 34311932

Oncopeptides

Oncopeptides

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

Oncopeptides phase 3 OCEAN study published in the Lancet Haematology

It looks like Oncopeptides isn’t giving up on their drug melflufen. The drug in combination with dexamethasone(anti inflammatory Glucocorticoids) seems to show better progression free survival than pomalidomide(another approved drug for cancer patients) statically yet they had still some safety issues which they are trying to tackle by dose adjustments. We saw somehow similar situation for Sutro’s ADC so the relevance of these data in comparison to THTX’s PDC is once they get that MTD coupled with some efficacy results now or later on as they will try the drug on more patients with various cancers they might have to adjust the dosage in case they face similar safety issues as long as the drug is effective in lower doses.

Point is the trial process is and will be fluid so that RP2D for Phase1b and behind can be adjusted later on based on both safety and efficacy results.

Even with those results their SP appreciated some 16%.

<< Previous
Bullboard Posts
Next >>